Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Burixafor [inn]
2. 1191448-17-5
3. Tg-0054
4. 2g17y0q20g
5. Phosphonic Acid, P-(2-(4-(6-amino-2-(((trans-4-(((3-(cyclohexylamino)propyl)amino)methyl)cyclohexyl)methyl)amino)-4-pyrimidinyl)-1-piperazinyl)ethyl)-
6. (2-(4-(6-amino-2-((((1r,4r)-4-(((3-(cyclohexylamino)propyl)amino)methyl)cyclohexyl)methyl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl)phosphonic Acid
7. Unii-2g17y0q20g
8. Burixafor [who-dd]
9. Chembl3545224
10. Schembl13332861
11. Schembl13354165
12. Schembl13354172
13. Schembl14693228
14. Schembl14693238
15. Tg0054
16. Db11970
17. Sb17205
18. Tg 0054
19. A857839
20. Q27254687
21. 2-[4-[6-amino-2-[[4-[[3-(cyclohexylamino)propylamino]methyl]cyclohexyl]methylamino]pyrimidin-4-yl]piperazin-1-yl]ethylphosphonic Acid
| Molecular Weight | 566.7 g/mol |
|---|---|
| Molecular Formula | C27H51N8O3P |
| XLogP3 | -0.1 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 14 |
| Exact Mass | 566.38217452 g/mol |
| Monoisotopic Mass | 566.38217452 g/mol |
| Topological Polar Surface Area | 152 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 724 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Burixafor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Burixafor, including repackagers and relabelers. The FDA regulates Burixafor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Burixafor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Burixafor supplier is an individual or a company that provides Burixafor active pharmaceutical ingredient (API) or Burixafor finished formulations upon request. The Burixafor suppliers may include Burixafor API manufacturers, exporters, distributors and traders.
Burixafor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Burixafor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Burixafor GMP manufacturer or Burixafor GMP API supplier for your needs.
A Burixafor CoA (Certificate of Analysis) is a formal document that attests to Burixafor's compliance with Burixafor specifications and serves as a tool for batch-level quality control.
Burixafor CoA mostly includes findings from lab analyses of a specific batch. For each Burixafor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Burixafor may be tested according to a variety of international standards, such as European Pharmacopoeia (Burixafor EP), Burixafor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Burixafor USP).
LOOKING FOR A SUPPLIER?
